Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) GF Value Rank : 2 (As of Apr. 28, 2024)

View and export this data going back to 1993. Start your Free Trial

What is Fresh Tracks Therapeutics GF Value Rank?

Fresh Tracks Therapeutics has the GF Value Rank of 2.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Fresh Tracks Therapeutics's GF Value Rank

For the Biotechnology subindustry, Fresh Tracks Therapeutics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fresh Tracks Therapeutics's GF Value Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fresh Tracks Therapeutics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Fresh Tracks Therapeutics's GF Value Rank falls into.

Fresh Tracks Therapeutics GF Value Rank Related Terms

Thank you for viewing the detailed overview of Fresh Tracks Therapeutics's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh Tracks Therapeutics Inc (OTCPK:FRTX) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

5777 Central Avenue, Suite 102, Boulder, CO, USA, 80301

Website

https://www.frtx.com

Fresh Tracks Therapeutics Inc is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics.

Executives

Monica E. Luchi	officer: Chief Medical Officer	430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Reginald L Hardy	director, officer: CHAIRMAN OF THE BOARD
David R. Mcavoy	officer: General Counsel and CCO	C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Deepak Chadha	officer: Chief Research & Dev. Officer	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Vijay B Samant	director	10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jose Breton	officer: Chief Accounting Officer	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Robert Busard Brown	director, officer: Chief Executive Officer	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Andrew D Sklawer	officer: COO and Secretary	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Dennison T Veru	director	C/O PALIDADE CAPITAL, ONE BRIDGE PLAZA NORTH #695, FORT LEE NJ 07024
Marchio Albert N Ii	officer: Chief Financial Officer
Gary A Lyons	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Sanjeev Ahuja	officer: Chief Medical Officer	121 3RD STREET NW, CARMEL IN 46032
Adam Scott Levy	officer: Chief Business Officer	C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
William Ju	director	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
R Michael Carruthers	officer: Chief Financial Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301